CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
Canakinumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01303380
NCT01303380Phase 2Completed
CompareCT.gov

An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)

Novartis Pharmaceuticals·interventional·Posted Feb 24, 2011·Updated Nov 5, 2015

In Brief

A Phase 2 clinical trial evaluating Canakinumab for Mevalonate Kinase Deficiency. Completed, enrolled 9 participants across 3 sites.

Detailed Summary

This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMevalonate Kinase Deficiency
CountriesSpain
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 24, 2011
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.4 years ago

Interventions

Canakinumabdrug